US4462990A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Biologically active substances, their obtainment from human casein and compositions containing said substances
Assignee: Institut National de la Santé et de la Recherche Médicale
•
Filing: 1981-10-02
•
Granted: 1984-07-31
•
Expires: 2001-10-02
Abstract
Abstract PCT No. PCT/FR81/00126 Sec. 371 Date May 21, 1982 Sec. 102(e) Date May 21, 1982 PCT Filed Oct. 2, 1981 PCT Pub. No. WO82/01131 PCT Pub. Date Apr. 15, 1982.New biologically active substances obtained by treating human casein with trypsin then fractionating and optionally purifying. They have immunological properties.
Inventors
- 👤 Pierre Jolles
- 👤 Daniele Migliore-Samour
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-07 12:08
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/46; C07K14/47; C07K14/4701; C07K14/4732; A; A61; A61K; A61K38/00; A61K38/01; A61K38/012; A61K38/018; Y; Y10; Y10S; Y10S530/00; Y10S530/806
Claims Analysis
Total Claims: 9
Claim 1
Independent Claim
120 words
A process for obtaining new biologically active immunological substances which stimulate the formation of antibodies and accelerate the phagocytosis phenomenon, which comprises treating a delipidated soluble human casein with at least one proteolytic enzyme selected from trypsin and chymotrypsin, the ratio enzyme/substrate being in the neighborhood of 1/100 for 24 hours at 37° C., then, after centrifugation, fractionating the hydrosoluble products as a function of their mean molecular weight by filtration on a suitable support with 30% acetic acid as eluant, and then isolating the biologically active substances comprising: (a) substance IV having a mean molecular weight of 5,300; (b) substance V having a mean molecular weight of 2,230; and (c) substance VI having a mean molecular weight of 1,120.
Claim 2
Dependent Claim
120 words
A process for obtaining new biologically active immunological substances which stimulate the formation of antibodies and accelerate the phagocytosis phenomenon, which comprises treating a delipidated soluble human casein with at least one proteolytic enzyme selected from trypsin and chymotrypsin, the ratio enzyme/substrate being in the neighborhood of 1/100 for 24 hours at 37° C., then, after centrifugation, fractionating the hydrosoluble products as a function of their mean molecular weight by filtration on a suitable support with 30% acetic acid as eluant, and then isolating the biologically active substances comprising: (a) substance IV having a mean molecular weight of 5,300; (b) substance V having a mean molecular weight of 2,230; and (c) substance VI having a mean molecular weight of 1,120.
Claim 3
Dependent Claim
114 words
The process of claim 1 wherein substance V is subsequently filtered on a suitable column with, as eluant, a buffer solution whose pH decreases, and isolating a substance of basic character named MJH-24 and substances of acidic character named MJH-63 and MJH-65, said substance of basic character being isolated after elution with a buffer solution of TRIS and 0.01 M HCl at pH 8, and said substances of acidic character being isolated after elution with a buffer solution of TRIS and 0.01 M HCl at pH 3.5 which is 0.1 N sodium chloride, and then with a buffer solution of TRIS and 0.01 M HCl at pH 3.5 which is 0.5 N sodium chloride.
Claim 4
Dependent Claim
23 words
A process according to claim 1, characterized in that it further comprises reacting the active substances obtained after filtration with a fatty acid.
Claim 5
Dependent Claim
18 words
A process according to claim 3, characterized in that the fatty acid is in an activated derivative form.
Claim 6
Dependent Claim
12 words
New biologically active immunological substances obtained by the process of claim 1.
Claim 7
Dependent Claim
12 words
New biologically active immunological substances obtained by the process of claim 2.
Claim 8
Dependent Claim
32 words
A biologically active immunological pharmaceutical composition, characterized in that it contains an effective amount of at least one substance according to claim 5, associated with one or more compatible diluents or adjuvants.
Claim 9
Dependent Claim
32 words
A biologically active immumological pharmaceutical composition, characterized in that it contains an effective amount of at least one substance according to claim 6, associated with one or more compatible diluents or adjuvants.
References Cited (Backward Citations)
US1631887A
Cited
US1658289A
Cited
US3186918A
Cited
US3323929A
Cited
FR1411478A
Cited
FR1461423A
Cited
FR1466141A
Cited
US3558770A
Cited
US4358465A
Cited
US4361587A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-07-31 | 1988-01-30 | 1988-07-31 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-07-31 | 1992-01-30 | 1992-07-31 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-07-31 | 1996-01-30 | 1996-07-31 | $7700.00 | Window Closed / Lapsed |